Humoral immune response against overexpressed oncogenic or tumor supressor proteins has been demonstrated for many types of cancer. In this study we report on the detection of the autologous antibody response to putative oncogene, human cortactin using serological analysis of breast carcinoma expression library. Cortactin maps to chromosome 11q13, the region ampli®ed in about 15% of primary breast carcinomas and 30% of head and neck squamous cell carcinomas. Cortactin overexpression due to such ampli®cation might aect adhesive properties of human cancer cells and is associated with poor disease prognosis. Accordingly, we detected overexpression of cortactin transcript in autologous tumor and ampli®ca-tion/overexpression of cortactin in tumors of breast cancer patients serologically positive for this marker. We demonstrate that 15% of breast cancer patients elicit humoral immune response against human cortactin. Oncogene (2000) 19, 5204 ± 5207.
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The development of cancer vaccines requires the identi®cation and characterization of tumor antigens. In the past decade many tumor antigens have been de®ned (reviewed by Old and Chen, 1998; Rosenberg, 1999) .
In 1991 T Boon and colleagues discovered the ®rst antigen recognized by cytotoxic T-lymphocytes (CTL) in human melanoma (van der Bruggen et al., 1991) . In their study tumor antigens have been identi®ed by the transfection of cDNA libraries into cells expressing the appropriate MHC molecule followed by the identi®ca-tion of transfectant using cytokine release or lysis by human T cells with speci®c antitumor reactivity (Boon et al., 1994) .
An alternative technique for the identi®cation of tumor antigens has been reported by Sahin et al. (1995) . This approach of serological analysis of cDNA expression libraries (SEREX), was based on previously described molecular screening techniques (D'Arpa et al., 1988) and exploited patient's B-cell repertoire for the identi®cation of human tumor antigens that show immunogenicity in the autologous host. Many antigens have been isolated by this technique, demonstrating that most, if not all, human cancers express multiple antigens including ampli®ed/overexpressed proteins with known cancer association (reviewed by Old and Chen, 1998; Disis and Cheever, 1996; Brass et al., 1999) .
In this study we applied the SEREX method to isolate and characterize candidate tumor antigens expressed in breast carcinoma. A cDNA library in phage expression vector (lambda ZAP Express) was prepared from a surgical tumor specimen of a 56-yearold woman with ER-positive breast carcinoma (T 1 M 0 N 0 ). The library was plated and screened with autologous patient's serum diluted 1 : 200 as previously described (Scanlan et al., 1998) The deduced amino acid sequence of MOBr-140 represents human cortactin from amino acid residue 112 ± 550, which is about 80% of entire protein sequence (Figure 1b) . This region, which apparently includes the epitope recognized by B cells, contains an SH3 domain at the C-terminus and ®ve and-a-half tandemly repeated copies of 37 amino acid residues (out of six and-a-half present in the full-size cortactin protein) that are believed to mediate binding of cortactin to ®lamentous actin in vitro. No evidence of mutations in this region was found in clone MOBr-140 as compared to published cortactin gene sequence (Schuuring et al., 1993 (Schuuring et al., , 1998 .
Human cortactin is a p80/p85 multidomain actin ®lament-binding protein (Schuuring et al., 1993 ) ®rst identi®ed as a src kinase substrate in chicken ®broblasts (Wu et al., 1991) . Cortactin is involved in the signaling pathway of mitogenic receptors and adhesion molecules mediating cytoskeletal reorganization (Schuuring et al., 1993 (Schuuring et al., , 1998 van Damme et al., 1997; Campbell et al., 1999) . Human cortactin maps to the chromosomal band 11q13 which is known to be ampli®ed in about 15% of primary breast carcinomas and 30% of head and neck squamous cell carcinoma (Schuuring, 1995; Meredith et al., 1995; Hui et al., 1998) . Such ampli®cation has been also reported for other malignancies, including ovarian and bladder cancer (Bringuier et al., 1996) . Ampli®cation of cortactin in breast and head and neck carcinomas is associated with poor clinical outcome. (Meredith et al., 1995; Schuuring et al., 1992 Schuuring et al., , 1995 Hui et al., 1998) . Additionally, recent studies have shown the overexpression of cortactin in NIH3T3 cells to result in increased cell invasion/migration in vitro (Patel et al., 1998; Huang et al., 1998) . Moreover, cortactin takes part in formation and function of invadopodias in (Bowden et al., 1999) supporting the hypothesis of direct involvement of cortactin in metastasis.
To examine the level of cortactin expression in tumor tissue used as the source of mRNA for preparation of the library, Northern blot analysis was performed. The results shown in Figure 2a demonstrate about sixfold overexpression of cortactin transcript in tumor tissue as compared to normal mammary gland tissue. Although overexpression of gene products in cancer can be caused by increased mRNA life span, increased protein stability, or gene ampli®cation (Disis and Cheever, 1996) , recent studies indicated that cortactin mRNA overexpression was associated predominantly with gene ampli®cation in some carcinomas (Hui et al., 1998) .
Unfortunately, DNA from autologous breast cancer tissue was unavailable for our study. We therefore analysed DNA and RNA samples from additional 12 tumor samples of breast cancer patients (Figure 2b,c) . Two of these 12 patients had humoral immunological response against cortactin (samples # #8 and 12). Two out of two tumor samples from patients serologically positive for cortactin showed both the ampli®cation of the cortactin gene (Figure 2b ) and the overexpression of cortactin mRNA (Figure 2c ), while none of 10 tumors from patients without antibody response showed signs of ampli®cation or overexpression.
In order to estimate the frequency of the immune response against human cortactin in cancer patients sera samples from normal donors and cancer patients were tested for their reactivity against expression clone MOBr-140 (Table 1) . None of the sera from normal donors age-matched with cancer patients showed reactivity, while about 15% of breast cancer sera elicited the immune response against this antigen. Three out of 11 sera of patients with head and neck squamous cell carcinoma also reacted with the clone MOBr-140. Additionally, one out of 20 ovarian cancer sera, one out of 25 renal cancer sera but not sera from lung cancer or melanoma, tested positive for MOBr-140 (Table 1) . Thus, human cortactin appears to display a cancer-restricted immunological pro®le and may be considered as a putative cancer antigen. Moreover, the results of screening of the clone MOBr-140 with a panel of breast cancer and head and neck squamous cell carcinoma sera are in good agreement with published data on average frequency of cortactin gene ampli®cation in primary breast carcinoma and head and neck squamous cell carcinoma (Hui et al., 1998; Meredith et al., 1995) .
Human immune response to oncogenic proteins has been reported in several studies (Disis and Cheever, 1996) and our ®ndings add human cortactin to this list. Further studies using larger panels of sera and tumor specimens is required to determine whether the presence of antibodies against this gene product in sera of cancer patients correlates with the tumor type and prognosis and could be valuable in cancer diagnostics. For determining the reactivity of allogeneic sera with MOBr-140, an equal number of phage clone MOBr-140 and negative control phage (wildtype lambda ZAP express phage) were transferred to nitrocellulose ®lters. After washing, membranes were incubated in a 1 : 200 dilution of allogeneic sera for 15 h at room temperature. Following a TBS wash step, the membranes were incubated in a 1 : 3000 dilution of alkaline phosphatase-conjugated, Fc fragment speci®c, goat anti-human IgG and the reactive phage plaques were visualized by incubating with 4-nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate
